Zmax Brochure: “Seek Emergency Help Right Away” Not Serious Enough, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients must be informed about severe and fatal reactions observed with a drug, not just told what to do if they occur, FDA tells Pfizer in untitled letter on Zmax brochure.
You may also be interested in...
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.
Drug Safety In Pregnant Women: FDA Seeks Alternatives To Registries
Stakeholder meeting will address poor enrollment rates and other issues that undermine the utility of pregnancy registries, as well as the use of alternatives, such as case control studies and claims-based database studies.